DEF: PharmaCyte Seeks Shareholder Approval for Financing, Equity Plan

PharmaCyte Biotech, Inc. calls a special meeting to approve a significant share issuance for recent financing and an increase in its equity incentive plan.

Summary

• A special meeting of stockholders is scheduled for October 30, 2025, to be held virtually.
• Stockholders will vote on three proposals: authorizing the issuance of shares related to a recent financing, amending the 2022 Equity Incentive Plan, and adjourning the meeting if necessary.
• The Issuance Proposal seeks approval for shares underlying Series C convertible preferred stock and warrants issued in an August 17, 2025 private placement, and warrants issued to GP Nurmenkari Inc. as placement agent.
• The financing transaction yielded gross proceeds of $7.0 million and was deemed necessary for general corporate purposes and working capital, given cash and cash equivalents of approximately $13.2 million as of July 31, 2025.
• The Series C Preferred Stock is initially convertible into up to 7,000,000 shares of common stock at $1.00 per share, and warrants allow purchase of up to 7,000,000 shares at $1.00 per share.
• GP Nurmenkari Inc. received warrants to purchase 560,000 shares of common stock at $1.00 per share.
• The Plan Amendment Proposal seeks to increase the number of shares available for awards under the 2022 Equity Incentive Plan by 2,250,000 shares, bringing the total authorized to 5,000,000 shares.
• The Board of Directors recommends approval of all three proposals.
• Failure to approve the Issuance Proposal could require the company to pay substantial cash amounts to holders of the securities, which it may not have sufficient funds to cover.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as the company has successfully secured necessary financing and is taking steps to ensure long-term incentive capabilities. However, the significant potential for shareholder dilution and the critical nature of the shareholder vote introduce a degree of caution.

Positives

• The recent financing provided $7.0 million in gross proceeds, improving the company's capital position and providing funds for working capital and general corporate purposes.
• The proposed amendment to the 2022 Equity Incentive Plan aims to attract, retain, and motivate key personnel by providing long-term, equity-based incentives.
• The additional 2,250,000 shares for the equity plan are expected to be sufficient for future granting needs for two additional years.

Negatives

• The potential issuance of common stock underlying the Series C Preferred Stock, Warrants, and GPN Warrants could result in significant dilution for current stockholders.
• The exact magnitude of the dilutive effect cannot be conclusively determined due to potential anti-dilution adjustments, but it may be material.
• Failure to approve the Issuance Proposal would prevent the company from issuing more than 20% of its outstanding common stock, potentially requiring substantial cash payments to security holders.
• The issuance or resale of common stock could cause the market price of the company's common stock to decline.

Risks

• Significant dilution of current stockholders' percentage ownership due to the potential issuance of up to 14,560,000 shares (plus anti-dilution provisions) from the financing and 2,250,000 shares from the equity incentive plan.
• Risk of not having sufficient funds to make substantial cash payments to security holders if the Issuance Proposal is not approved and the company is unable to issue shares.
• Potential decline in the market price of common stock due to the issuance or resale of shares from the financing.
• The increased number of issued shares could have an incidental anti-takeover effect, making certain mergers, tender offers, or change of control transactions more difficult.

Future Outlook

The company believes the additional 2,250,000 shares available for issuance under the 2022 Equity Incentive Plan will be adequate for future granting needs for two additional years following the current year. The proceeds from the recent financing and potential warrant exercises are expected to improve the capital position and provide financing for working capital and general corporate purposes.

Management Comments

• Joshua Silverman, Executive Chairman, stated: 'We hope you will be able to attend the special meeting. Whether you plan to attend the special meeting or not, it is important that you cast your vote either in person or by proxy. We encourage you to vote by proxy so that your shares will be represented and voted at the meeting, whether or not you can attend. Thank you for your continued support of the Company.'

Industry Context

This filing primarily addresses corporate financing and governance matters specific to PharmaCyte Biotech, Inc. and does not provide broader industry trend analysis or competitive positioning. The need for capital raising is common for biotech companies in development stages.

Comparison to Industry Standards

• NA

Corporate Governance

Stakeholder Impact

• Shareholders: Face potential significant dilution from the issuance of shares related to the financing and the increase in the equity incentive plan. However, approval of the Issuance Proposal is crucial to avoid substantial cash payment obligations that could jeopardize the company's business plan.
• Employees, Directors, and Consultants: Will benefit from the expanded 2022 Equity Incentive Plan, which provides more shares for stock-based compensation, aiding in attraction and retention.
• Investors in the private placement: Their ability to convert preferred stock and exercise warrants is contingent on shareholder approval of the Issuance Proposal, which is a condition for them to receive the full benefit of their investment.

Next Steps

• Hold a special meeting of stockholders on October 30, 2025, to vote on the Issuance Proposal, Plan Amendment Proposal, and Adjournment Proposal.
• If necessary, adjourn the special meeting to solicit additional proxies if there are insufficient votes for the proposals or to establish a quorum.
• Publish preliminary or final voting results in a Current Report on Form 8-K within four business days of the special meeting.

Key Dates

Recommendation

The company has secured crucial financing, which is a positive for its operational continuity and working capital needs. However, the proposed share issuances, if approved, will lead to significant dilution for existing shareholders. The proposals are presented as necessary to avoid substantial cash payment obligations and to maintain competitive employee incentives. Given the necessity of these actions for the company's ongoing viability, a 'hold' recommendation is appropriate, acknowledging both the essential capital infusion and the dilutive impact, while awaiting the outcome of the shareholder vote and subsequent operational performance.

Keywords

PharmaCyte Biotech, SEC Filing, Proxy Statement, Shareholder Meeting, Equity Incentive Plan, Stock Issuance, Convertible Preferred Stock, Warrants, Dilution, Nasdaq Listing Rule 5635(d), Capital Raise, Corporate Governance